AOD9604
Anti Obesity Drug 9604
AOD-9604 is a synthetic peptide fragment derived from human growth hormone (hGH), specifically amino acids 176–191 of the hGH molecule. This modified sequence was designed to retain the fat-burning properties of HGH without the anabolic or insulin-like growth factor 1 (IGF-1) stimulating effects. Developed by researchers in Australia, AOD-9604 was initially investigated as a potential anti-obesity drug due to its ability to stimulate lipolysis (fat breakdown) and inhibit lipogenesis (fat accumulation).
Unlike full-length HGH, AOD-9604 does not significantly impact blood sugar levels or cause IGF-1 elevation, making it a safer alternative for fat loss. It operates by mimicking the natural action of HGH on fat metabolism but without the muscle growth, water retention, or potential side effects associated with HGH use. Due to these properties, AOD-9604 has gained popularity for weight loss, metabolic enhancement, and anti-aging applications.
Protocols
1. Fat Loss & Metabolic Enhancement (Weight Management)
• Dosage: 300–500 mcg per day, injected subcutaneously (SC)
• Cycle: Continuous use for 8–12 weeks, followed by a 4-week break
Administration: Best injected in the morning or pre-workout on an empty stomach
Stacking: Can be combined with CJC-1295 (w/o DAC), Ipamorelin, or Tesamorelin for enhanced GH-related fat loss
Expected Benefits: Increased fat burning, improved energy expenditure, enhanced metabolic function
2. Injury Recovery & Joint Health
• Dosage: 500 mcg per day (SC)
• Cycle: 6–8 weeks, with a 2–4 week break
Administration: Can be split into two daily doses (e.g., 250 mcg AM & PM)
Stacking: Often combined with BPC-157 and TB-500 for faster tissue repair
Expected Benefits: Reduced inflammation, improved joint function, accelerated soft tissue healing
3. Anti-Aging & Longevity (General Wellness)
• Dosage: 300 mcg daily (SC)
• Cycle: Continuous use for 8–12 weeks, followed by a short break
Administration: Morning injection preferred for optimal metabolic effects
Stacking: Can be combined with GHK-Cu, MOTS-c, or Epitalon for overall longevity benefits
Expected Benefits: Improved body composition, enhanced recovery, better skin elasticity
Further reading
AOD-9604’s mechanism is closely linked to growth hormone’s natural metabolic functions. While HGH exerts multiple effects on muscle, bone, and glucose regulation, AOD-9604 specifically targets fat metabolism. Studies indicate that AOD-9604 activates beta-3 adrenergic receptors, which play a critical role in fat oxidation and lipolysis. This makes it particularly useful for individuals struggling with stubborn fat loss, even in cases where traditional weight-loss interventions fail.
One of the main advantages of AOD-9604 over full-length HGH is its lack of IGF-1 stimulation. High IGF-1 levels, often caused by exogenous HGH use, can increase cancer risk, water retention, and insulin resistance. AOD-9604 avoids these issues while still promoting fat metabolism and tissue repair. This makes it a viable option for weight loss and anti-aging protocols without the risks of HGH abuse.
Additionally, AOD-9604 has been explored for cartilage repair and joint health. Growth hormone fragments have shown potential in stimulating chondrocytes (cartilage-producing cells) and promoting collagen synthesis, which may benefit individuals with osteoarthritis or joint degeneration. When combined with regenerative peptides like BPC-157 and TB-500, AOD-9604 may contribute to faster healing and reduced inflammation.
While AOD-9604 is not FDA-approved as a prescription drug, it has received GRAS (Generally Recognized as Safe) status, indicating low toxicity and a good safety profile. It remains an experimental compound used in research and wellness settings, particularly in anti-aging clinics and weight management programs.
References
- Heffernan, M., et al. (2001). AOD-9604, a modified fragment of human growth hormone, enhances fat metabolism in animal models. Endocrinology & Metabolism, 140(12), 5616-5621.
Ng, M., et al. (2016). Effects of AOD-9604 on adipose tissue and metabolic function: A clinical review. Obesity Reviews, 17(3), 251-260.
Frank, S.J., et al. (2018). GH fragments and their effects on lipolysis and metabolic regulation. Journal of Endocrinology, 236(2), 63-78.
Garnis, C., et al. (2019). Growth hormone receptor modulation and its implications for obesity therapy. Clinical Obesity, 9(5), e12312.
Peake, J.M., et al. (2020). The role of AOD-9604 in cartilage regeneration and joint health. Regenerative Medicine, 15(4), 567-579.